KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,495,607 | -8.3% | 486,001 | +15.5% | 0.00% | 0.0% |
| Q2 2023 | $16,904,609 | +7.6% | 420,722 | +14.3% | 0.00% | 0.0% |
| Q1 2023 | $15,715,564 | +93478.4% | 368,046 | +5.2% | 0.00% | 0.0% |
| Q4 2022 | $16,794 | -99.9% | 349,748 | +10.6% | 0.00% | 0.0% |
| Q3 2022 | $11,893,000 | +56.6% | 316,149 | +15.0% | 0.00% | +100.0% |
| Q2 2022 | $7,595,000 | -49.2% | 274,902 | +0.0% | 0.00% | -50.0% |
| Q1 2022 | $14,945,000 | -0.1% | 274,843 | +7.5% | 0.00% | 0.0% |
| Q4 2021 | $14,963,000 | +77.8% | 255,747 | +20.2% | 0.00% | +100.0% |
| Q3 2021 | $8,418,000 | -10.1% | 212,806 | -3.5% | 0.00% | 0.0% |
| Q2 2021 | $9,365,000 | -12.6% | 220,527 | +26.7% | 0.00% | -50.0% |
| Q1 2021 | $10,710,000 | -3.6% | 174,021 | +10.5% | 0.00% | 0.0% |
| Q4 2020 | $11,107,000 | +161.8% | 157,460 | +43.1% | 0.00% | +100.0% |
| Q3 2020 | $4,243,000 | +5.5% | 110,028 | +2.6% | 0.00% | 0.0% |
| Q2 2020 | $4,022,000 | – | 107,228 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |